Menu Search
Equities

AC Immune SA

ACIU:NMQ

AC Immune SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.20
  • Today's Change-0.07 / -2.14%
  • Shares traded74.23k
  • 1 Year change+6.67%
  • Beta1.2380
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year AC Immune SA grew revenues 276.14% from 3.94m to 14.80m while net income improved from a loss of 70.75m to a smaller loss of 54.23m.
Gross margin--
Net profit margin-390.68%
Operating margin-387.63%
Return on assets-30.73%
Return on equity-46.06%
Return on investment-42.90%
More ▼

Cash flow in CHFView more

In 2023, AC Immune SA increased its cash reserves by 148.51%, or 46.91m. Cash Flow from Investing totalled 65.65m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 60.41m for operations while cash generated from financing totalled 43.25m.
Cash flow per share-0.7193
Price/Cash flow per share--
Book value per share1.42
Tangible book value per share0.8409
More ▼

Balance sheet in CHFView more

AC Immune SA has little financial risk as the capital structure does not rely on leverage.
Current ratio1.80
Quick ratio--
Total debt/total equity0.0262
Total debt/total capital0.0255
More ▼

Growth rates in CHF

Year on year, growth in earnings per share excluding extraordinary items increased 24.38%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		19.20
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.